Literature DB >> 17456594

The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans.

Alana L Welm1, Julie B Sneddon, Carmen Taylor, Dimitry S A Nuyten, Marc J van de Vijver, Bruce H Hasegawa, J Michael Bishop.   

Abstract

A better understanding of tumor metastasis requires development of animal models that authentically reproduce the metastatic process. By modifying an existing mouse model of breast cancer, we discovered that macrophage-stimulating protein promoted breast tumor growth and metastasis to several organs. A special feature of our findings was the occurrence of osteolytic bone metastases, which are prominent in human breast cancer. To explore the clinical relevance of our model, we examined expression levels of three genes involved in activation of the MSP signaling pathway (MSP, MT-SP1, and MST1R) in human breast tumors. We found that overexpression of MSP, MT-SP1, and MST1R was a strong independent indicator of both metastasis and death in human breast cancer patients and significantly increased the accuracy of an existing gene expression signature for poor prognosis. These data suggest that signaling initiated by MSP is an important contributor to metastasis of breast cancer and introduce an independent biomarker for assessing the prognosis of humans with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17456594      PMCID: PMC1855278          DOI: 10.1073/pnas.0702095104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation.

Authors:  Glendon M Zinser; Mike A Leonis; Kenya Toney; Peterson Pathrose; Megan Thobe; Sarah A Kader; Belinda E Peace; Shirelyn R Beauman; Margaret H Collins; Susan E Waltz
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

2.  MET and MYC cooperate in mammary tumorigenesis.

Authors:  Alana L Welm; Suwon Kim; Bryan E Welm; J Michael Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-28       Impact factor: 11.205

3.  Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients.

Authors:  Wen-Ying Lee; Helen H W Chen; Nan-Haw Chow; Wu-Chou Su; Pin-Wen Lin; How-Ran Guo
Journal:  Clin Cancer Res       Date:  2005-03-15       Impact factor: 12.531

4.  Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway.

Authors:  Ami S Bhatt; Alana Welm; Christopher J Farady; Maximiliano Vásquez; Keith Wilson; Charles S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-27       Impact factor: 11.205

5.  Prognostic value of ERBB family mRNA expression in breast carcinomas.

Authors:  Ivan Bièche; Peter Onody; Sengül Tozlu; Keltouma Driouch; Michel Vidaud; Rosette Lidereau
Journal:  Int J Cancer       Date:  2003-09-20       Impact factor: 7.396

6.  The MSP receptor regulates alpha6beta4 and alpha3beta1 integrins via 14-3-3 proteins in keratinocyte migration.

Authors:  Massimo M Santoro; Giovanni Gaudino; Pier Carlo Marchisio
Journal:  Dev Cell       Date:  2003-08       Impact factor: 12.270

Review 7.  Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase.

Authors:  Ming-Hai Wang; Da Wang; Yi-Qing Chen
Journal:  Carcinogenesis       Date:  2003-05-22       Impact factor: 4.944

8.  The molecular portraits of breast tumors are conserved across microarray platforms.

Authors:  Zhiyuan Hu; Cheng Fan; Daniel S Oh; J S Marron; Xiaping He; Bahjat F Qaqish; Chad Livasy; Lisa A Carey; Evangeline Reynolds; Lynn Dressler; Andrew Nobel; Joel Parker; Matthew G Ewend; Lynda R Sawyer; Junyuan Wu; Yudong Liu; Rita Nanda; Maria Tretiakova; Alejandra Ruiz Orrico; Donna Dreher; Juan P Palazzo; Laurent Perreard; Edward Nelson; Mary Mone; Heidi Hansen; Michael Mullins; John F Quackenbush; Matthew J Ellis; Olufunmilayo I Olopade; Philip S Bernard; Charles M Perou
Journal:  BMC Genomics       Date:  2006-04-27       Impact factor: 3.969

9.  Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay.

Authors:  Laurent Perreard; Cheng Fan; John F Quackenbush; Michael Mullins; Nicholas P Gauthier; Edward Nelson; Mary Mone; Heidi Hansen; Saundra S Buys; Karen Rasmussen; Alejandra Ruiz Orrico; Donna Dreher; Rhonda Walters; Joel Parker; Zhiyuan Hu; Xiaping He; Juan P Palazzo; Olufunmilayo I Olopade; Aniko Szabo; Charles M Perou; Philip S Bernard
Journal:  Breast Cancer Res       Date:  2006-04-20       Impact factor: 6.466

10.  Repeated observation of breast tumor subtypes in independent gene expression data sets.

Authors:  Therese Sorlie; Robert Tibshirani; Joel Parker; Trevor Hastie; J S Marron; Andrew Nobel; Shibing Deng; Hilde Johnsen; Robert Pesich; Stephanie Geisler; Janos Demeter; Charles M Perou; Per E Lønning; Patrick O Brown; Anne-Lise Børresen-Dale; David Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-26       Impact factor: 12.779

View more
  78 in total

1.  Meeting report: Metastasis Research Society-Chinese Tumor Metastasis Society joint conference on metastasis.

Authors:  Katherine Bankaitis; Lucia Borriello; Thomas Cox; Conor Lynch; Andries Zijlstra; Barbara Fingleton; Miodrag Gužvić; Robin Anderson; Josh Neman
Journal:  Clin Exp Metastasis       Date:  2017-03-04       Impact factor: 5.150

2.  Positional scanning synthetic combinatorial libraries for substrate profiling.

Authors:  Eric L Schneider; Charles S Craik
Journal:  Methods Mol Biol       Date:  2009

3.  Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase.

Authors:  Daniel R Sharda; Shan Yu; Manujendra Ray; Mario Leonardo Squadrito; Michele De Palma; Thomas A Wynn; Sidney M Morris; Pamela A Hankey
Journal:  J Immunol       Date:  2011-08-01       Impact factor: 5.422

Review 4.  Lessons in signaling and tumorigenesis from polyomavirus middle T antigen.

Authors:  Michele M Fluck; Brian S Schaffhausen
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

5.  Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition.

Authors:  Christopher J Farady; Pascal F Egea; Eric L Schneider; Molly R Darragh; Charles S Craik
Journal:  J Mol Biol       Date:  2008-05-11       Impact factor: 5.469

6.  Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.

Authors:  Magdalena Bieniasz; Parvathi Radhakrishnan; Najme Faham; Jean-Paul De La O; Alana L Welm
Journal:  Clin Cancer Res       Date:  2015-08-19       Impact factor: 12.531

7.  Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity.

Authors:  Henok Eyob; Huseyin Atakan Ekiz; Yoko S Derose; Susan E Waltz; Matthew A Williams; Alana L Welm
Journal:  Cancer Discov       Date:  2013-04-23       Impact factor: 39.397

8.  Genetic and epigenetic somatic alterations in head and neck squamous cell carcinomas are globally coordinated but not locally targeted.

Authors:  Graham M Poage; Brock C Christensen; E Andres Houseman; Michael D McClean; John K Wiencke; Marshall R Posner; John R Clark; Heather H Nelson; Carmen J Marsit; Karl T Kelsey
Journal:  PLoS One       Date:  2010-03-11       Impact factor: 3.240

9.  Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression.

Authors:  Satoru Sugie; Shoichiro Mukai; Koji Yamasaki; Toyoharu Kamibeppu; Hiromasa Tsukino; Toshiyuki Kamoto
Journal:  Hum Cell       Date:  2015-08-07       Impact factor: 4.174

10.  The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells.

Authors:  M N Thobe; D Gurusamy; P Pathrose; S E Waltz
Journal:  Oncogene       Date:  2009-10-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.